Restorative impact of rabeprazole on gastric mucus and mucin production impairment during naproxen administration: Its potential clinical significance

Digestive Diseases and Sciences

Volumn 50, Issue 2, 2005, Pages 357-365

  Jaworski, T ^a   Sarosiek, I ^a   Sostarich, S ^a   Roeser, K ^a   Connor, M ^a   Brotze, S ^a   Wallner, G ^a,b   Sarosiek, J ^a,c  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Gastric mucin; Gastric mucus; Mucous barrier; Naproxen

Indexed keywords

MUCIN; NAPROXEN; PENTAGASTRIN; RABEPRAZOLE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DENSITY GRADIENT CENTRIFUGATION; DIALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FREEZE DRYING; GRAVIMETRY; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; STOMACH JUICE; STOMACH MUCOSA LESION; STOMACH MUCUS;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZIMIDAZOLES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; EXOCRINE GLANDS; FEMALE; GASTRIC JUICE; GASTRIC MUCIN; HUMANS; MALE; MIDDLE AGED; MUCUS; NAPROXEN; OMEPRAZOLE; PROTON-TRANSLOCATING ATPASES;

EID: 14644416007     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-1611-3     Document Type: Article

References (35)

1. Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520-1528, 2000
2. Laine L, Marin-Sorensen M, Weinstein WM: Nonsteroidal antiinflammatory drug-associated gastric ulcers do not require Helicobacter pylori for their development. Am J Gastroenterol 87:1398-1402, 1992
3. Sarosiek J, Marcinkiewicz M, Parolisi S, et al.: The content of prostaglandin E2 in residual gastric juice reflects endoscopic damage to the gastric mucosa after naproxen sodium administration. Am J Gastroenterol 91:873-878, 1996
4. Marcinkiewicz M, Sarosiek J, Peura DA: The relationship between the content of gastric mucus protective components in gastric juice and endoscopic damage to the gastric mucosa after naproxen sodium administration. Am J Gastroenterol 91:360-365, 1996
5. Sarosiek J, Marshall BJ, Peura DA, et al.: Gastroduodenal mucus gel thickness in patients with Helicobacter pylori: A method for assessment of biopsy specimens. Am J Gastroenterol 86:729-734, 1991
6. Slomiany BL, Sarosiek J, Slomiany A: Gastric mucus and the mucosal barrier. Dig Dis 5:125-145, 1987
7. Allen A: Structure and function of gastrointestinal mucus. In: Johnson LR (ed). Physiology of the Gastrointestinal Tract. New York, Raven Press, 1981, pp. 617-639
8. Allen A, Flemstrom G, Garner A, et al.: Gastroduodenal mucosal protection. Physiol Rev 73:823-857, 1993
9. Peterson WL, Barnett CC, Evans DJ Jr, et al.: Acid secretion and serum gastrin in normal subjects and patients with duodenal ulcer: the role of Helicobacter pylori [see comments]. Am J Gastroenterol 88:2038-2043, 1993
10. Hunt RH: Hp and pH: Implications for the eradication of Helicobacter pylori. Scand J Gastroenterol Suppl 19:12-6-12-16, 1993
11. Wormsley KG: Campylobacter pylori and ulcer disease - A causal connection. Scand J Gastroenterol Suppl 160:53-58, 1989
12. Sarosiek J, Mizuta K, Slomiany A, et al.: Effect of acetylsalicylic acid on gastric mucin viscosity, permeability to hydrogen ion and susceptibility to pepsin. Biochem Pharmacol 35:4291-4295, 1986
13. Sarosiek J, Slomiany A, Slomiany BL: Retardation of hydrogen ion diffusion by gastric mucus constituents: Effect of proteolysis. Biochem Biophys Res Commun 113:1053-1060, 1983
14. Sarosiek J, Slomiany A, Slomiany BL: Evidence for weakening of gastric mucus integrity by Campylobacter pylori. Scand J Gastroenterol 23:585-590, 1988
15. Sarosiek J, Feng T, McCallum RW: The interrelationship between salivary epidermal growth factor and the functional integrity of the esophageal mucosal barrier in the rat. Am J Med Sci 302:359-363, 1991
16. Bilski J, Sarosiek J, Murty VLN, et al.: Enhancament of the lipid content and physical properties of gastric mucus by geranylgeranylacetone. Biochem Pharmacol 36:4059-4065, 1987
17. Azuumi Y, Ohara S, Ishihara K, et al.: Correlation of quantitative changes of gastric mucosal glycoproteins with aspirin-induced gastric damage in rats. Gut 21:533-536, 1980
18. + ATPase. Annu Rev Pharmacol Toxicol 35:277-305, 1995
19. Takiuchi H, Asada S, Umegaki E, et al.: Effects of proton pump inhibitors: omeprazole, lansoprazole, and E-3810 on the gastric mucin. 1404P, 1994 (abstract)
20. Skoczylas T, Sarosiek I, Sostarich S, et al.: Significant enhancement of gastric mucin content after rabeprazole administration: Its potential clinical significance in acid-related disorders. Dig Dis Sci 48:322-328, 2003
21. Namiot Z, Sarosiek J, Rourk RM, et al.: Human esophageal secretion: Mucosal response to luminal acid and pepsin. Gastroenterology 106:973-981, 1994
22. Richardson C, Emery P: The clinical implications of inhibition of the inducible form of cyclo-oxygenase. Drug Saf 15:249-260, 1996
23. Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 38:97-120, 1998 (abstract)
24. Laine L, Harper S, Simon T, et al.: A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteorthritis. Gastroenterology 117:776-783, 1999
25. Sachs G: Proton pump inhibitors and acid-related diseases. Pharmacotherapy 17:22-37, 1997
26. Zalewsky CA, Moody FG: Mechanisms of mucus release in exposed canine gastric mucosa. Gastroenterology 79:719-730, 1979
27. Sarosiek J, Slomiany A, Takagi T, et al.: Hydrogen ion diffusion in dog gastric mucus glycoprotein: Effect of associated lipids and covalently bound fatty acids. Biochem Biophys Res Commun 118:523-531, 1984
28. Quigley EMM, Turnberg LA: pH of the microclimate lining human gastric and duodenal mucosa in vivo: Studies in control subjects and in duodenal ulcer patients. Gastroenterology 92:1976-1984, 1987
29. Namiot Z, Sarosiek J, Marcinkiewicz M, et al.: Declined human esophageal mucin secretion in patients with severe reflux esophagitis. Dig Dis Sci 39:2523-2529, 1994
30. Slomiany BL, Murty VLN, Sarosiek J, et al.: Role of associated and covalently bound lipids in salivary mucin hydrophobicity: Effect of proteolysis and disulphide bridge reduction. Biochem Biophys Res Commun 151:1046-1053, 1988
31. Hills BA, Butler BD, Lichtenberger LM: Gastric mucosal barrier: Hydrophobic lining to the lumen of the stomach. Am J Physiol 244:G561-G568, 1983
32. Go MF, Lew GM, Lichtenberger LM, et al.: Gastric mucosal hydrophobicity and Helicobacter pylori: Response to antimicrobial therapy. Am J Gastroenterol 88:1362-1365, 1993
33. DeRosa J, Marcinkiewicz M, Sarosiek J, et al.: Modulatory impact of acid and pepsin on esophageal hydrophobicity in human. Am J Gastroenterol 90:2020-2024, 1995
34. Sarosiek J, Peura D, Guerrant RL, et al.: Mucolytic effects of Helicobacter pylori. Sc J Gastroenterol 1991;26, Suppl. 187:47-55.
35. Sarosiek J, Namiot Z, Marshall BJ, et al.: Breakdown of the mucus layer by H. pylori. In: Hunt RH, Tytgat GNJ, eds. Helicobacter pylori: Basic mechanisms to clinical cure. Kluwer Academic Publishers: Dordrecht/Boston/ London, 1994:123-138